TABLE 1.
Clinicopathologic characteristic of patients who underwent curative resection
| Characteristic | Total (n = 180) | No recurrence (n = 64) | Recurrence (n = 116) | p value |
|---|---|---|---|---|
| Age, years, median (IQR) | 52 (43–61) | 51 (41.5–61.5) | 53.5 (43–61) | 0.76 |
| Female, n (%) | 115 (63.9) | 42 (65.6) | 73 (62.9) | 0.72 |
| White race, (n = 175) | 144 (82.3) | 54 (85.7) | 90 (80.4) | 0.52 |
| Incidental finding, (n = 170) | 80 (47.1) | 34 (53.1) | 45 (43.4) | 0.21 |
| Hormone functional, (n = 166) | ||||
| Nonsecreting | 102 (61.5) | 43 (68.2) | 59 (57.3) | 0.54 |
| Cortisol | 35 (21.1) | 11 (17.5) | 24 (23.3) | |
| Mineralocorticoid | 8 (4.8) | 2 (3.2) | 6 (5.8) | |
| Sex hormone | 21 (12.6) | 7 (11.1) | 14 (13.6) | |
| Laterality (n = 177) | ||||
| Right | 82 (46.3) | 35 (55.6) | 47 (41.2) | 0.07 |
| Left | 95 (53.7) | 28 (44.4) | 67 (58.8) | |
| T stage (n = 162) | ||||
| T1 | 11 (6.8) | 7 (11.7) | 4 (4.0) | 0.005 |
| T2 | 74 (45.7) | 35 (58.3) | 39 (38.2) | |
| T3 | 62 (38.3) | 14 (23.3) | 48 (47.0) | |
| T4 | 15 (9.2) | 4 (6.7) | 11 (10.8) | |
| N stage | ||||
| N0 | 33 (18.3) | 12 (18.8) | 21 (18.1) | 0.2 |
| N1 | 16 (8.9) | 3 (4.7) | 13 (11.2) | |
| Nx | 131 (72.8) | 49 (76.5) | 82 (70.7) | |
| Tumor size, cm, median (IQR) | 11 (7.5–14.3) | 9.5 (6.5–13) | 12 (8–15.4) | 0.005 |
| Capsular invasion, (n = 120) | 71 (59.2) | 20 (44.4) | 51 (68.0) | 0.01 |
| Time between diagnosis and surgery, months, median (IQR) | 1.12 (0.56–2.34) | 1.07 (0.6–2.8) | 1.18 (0.4–2.2) | 0.59 |
| Operation type, (n = 172) | ||||
| Open abdominal or posterior | 111 (64.5) | 39 (61.9) | 72 (66.1) | 0.34 |
| Minimally invasive surgery | 38 (22.1) | 18 (28.6) | 20(18.3) | |
| Thoracoabdominal surgery | 23 (13.4) | 6 (9.5) | 17 (15.6) | |
| Margin (n = 156) | ||||
| R0 | 117 (75.0) | 45 (75.0) | 72 (75.0) | 1.0 |
| R1 | 39 (25.0) | 15 (25.0) | 24 (25.0) | |
| Multiorgan resection | 67 (39.6) | 22 (34.4) | 45 (42.9) | 0.27 |
| Neoadjuvant chemotherapy (n = 169) | 2 (1.2) | 1 (1.6) | 1 (1.0) | 0.74 |
| Adjuvant chemotherapy (n = 172)* | 61 (35.5) | 19 (30.2) | 42 (38.5) | 0.27 |
| Adjuvant radiotherapy (n = 147)* | 14 (9.5) | 5 (8.7) | 9 (10.1) | 0.81 |
| Adjuvant mitotane (n = 150) | 54 (36.0) | 17 (32.1) | 37 (38.1) | 0.46 |
IQR interquartile range
*
2 patients received both adjuvant chemotherapy and radiotherapy